Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07015905 · ClinicalTrials.gov registry record · Phase 3
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
A Phase 3 study of Venous Thromboembolism (VTE), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
- 20
- Study locations
NCT07015905 is a Phase 3 study of Venous Thromboembolism (VTE) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 2,000 participants, below the 14,772-participant average among 3 other Venous Thromboembolism (VTE) trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT07015905, a Phase 3 study of Venous Thromboembolism (VTE), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Apixaban
- DRUG REGN7508
- DRUG Enoxaparin
Study Locations (20)
Florida
- Delray Physician Care Center - Delray Beach
- Bioresearch Partner - Miami
- Sacred Heart Health System Inc - Pensacola
- Gulfcoast Research Institute - Sarasota
- Phoenix Clinical Research - Tamarac
Texas
- HD Research - First Surgical Hospital - Bellaire
- University of Texas (UT); Southwestern Medical Center - Dallas
- NextStage Clinical Research, All American Orthopedics and Sports Medicine - Houston
- Futuro Clinical Trials - McAllen
- Flourish Research - San Antonio (Formerly Clinical Trials of Texas) - San Antonio
Other
- Multi-profile Hospital for Active Treatment Hearth and Brain EAD - Pleven
- Multiprofile Hospital for Active Treatment; Sveta Sofia EOOD (MBAL Sveta Sofia), - Sofia
Alabama
- Shoals Medical Trials, Inc. - Sheffield
California
- CARI Clinical Trials - Riverside
Colorado
- Denver Metro Orthopedics, P.C. Englewood Location - Englewood
Maryland
- Sinai Hospital of Baltimore, Inc. - Baltimore
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2025-06-25 |
| Est. Completion | 2027-05-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07015905
The ClinicalTrials.gov registry entry for NCT07015905 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 14,772-participant average among 3 other Venous Thromboembolism (VTE) trials with a reported enrollment target (86% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Venous Thromboembolism (VTE) appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT07015905 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT07015905 about?
NCT07015905 is a clinical study titled "REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults". This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) a...
What is the current status of trial NCT07015905?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2025-06-25. Estimated completion is 2027-05-12.
What conditions does trial NCT07015905 study?
This clinical trial studies the following conditions: Venous Thromboembolism (VTE).
What interventions are being tested in trial NCT07015905?
The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG), REGN7508 (DRUG), Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT07015905?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07015905 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism (VTE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cancer Venous Thromboembolism (VTE)
COMPLETED · Phase 3
-
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
COMPLETED · Phase 3
-
A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.